Researcher index
Authors in the psilocybin and psilocin literature
Search researcher names, inspect publication history, find recurring topics, and create author watch alerts without collecting unverified contact lists.
Publication history
An international mega-analysis of psychedelic drug effects on brain circuit function.Nature medicine · 2026-04-01Ketamine and Psilocybin Differentially Impact Sensory Learning During the Mismatch NegativitybioRxiv · 2025-11-07Epigenome-wide Association Study of Psilocybin-Induced Methylome Changes in Alcohol Use DisorderbioRxiv · 2025-07-18Psilocybin increases emotional empathy in patients with major depression.Molecular psychiatry · 2025-06-01A Field-Wide Review and Analysis of Study Materials Used in Psilocybin Trials: Assessment of Two Decades of Research.Psychedelic medicine (New Rochelle, N.Y.) · 2025-03-01Neural Mechanisms of Resting-State Networks and the Amygdala Underlying the Cognitive and Emotional Effects of Psilocybin.Biological psychiatry · 2024-07-01The influence of psilocybin on subconscious and conscious emotional learning.iScience · 2024-06-21Comparing Neural Correlates of Consciousness: From Psychedelics to Hypnosis and Meditation.Biological psychiatry. Cognitive neuroscience and neuroimaging · 2024-05-01Author Correction: Psilocybin enhances insightfulness in meditation: a perspective on the global topology of brain imaging during meditation.Scientific reports · 2024-04-23Psilocybin enhances insightfulness in meditation: a perspective on the global topology of brain imaging during meditation.Scientific reports · 2024-03-26Psilocybin-induced changes in cerebral blood flow are associated with acute and baseline inter-individual differences.Scientific reports · 2023-10-14TMS-EEG and resting-state EEG applied to altered states of consciousness: oscillations, complexity, and phenomenology.iScience · 2023-05-19Single-dose psilocybin-assisted therapy in major depressive disorder: A placebo-controlled, double-blind, randomised clinical trial.EClinicalMedicine · 2023-02-01Corrigendum to 'Single-dose psilocybin-assisted therapy in major depressive disorder: a placebo-controlled, double-blind, randomised clinical trial'.EClinicalMedicine · 2023-02-01Neural mechanisms of psychedelic visual imagerymedRxiv · 2022-09-09Effective connectivity of emotion and cognition under psilocybinmedRxiv · 2022-09-09Psilocybin Induces Aberrant Prediction Error Processing of Tactile Mismatch Responses-A Simultaneous EEG-FMRI Study.Cerebral cortex (New York, N.Y.: 1991) · 2021-11-23P300-mediated modulations in self-other processing under psychedelic psilocybin are related to connectedness and changed meaning: A window into the self-other overlap.Human brain mapping · 2020-12-01Psilocybin Induces Time-Dependent Changes in Global Functional Connectivity.Biological psychiatry · 2020-07-15Rostral Anterior Cingulate Thickness Predicts the Emotional Psilocybin Experience.Biomedicines · 2020-02-18Characterization and prediction of acute and sustained response to psychedelic psilocybin in a mindfulness group retreat.Scientific reports · 2019-10-24Psilocybin exerts distinct effects on resting state networks associated with serotonin and dopamine in micebioRxiv · 2019-09-01Psilocybin-assisted mindfulness training modulates self-consciousness and brain default mode network connectivity with lasting effects.NeuroImage · 2019-08-01Psilocybin modulates functional connectivity of the amygdala during emotional face discrimination.European neuropsychopharmacology: the journal of the European College of Neuropsychopharmacology · 2018-06-01Serotonergic Hallucinogen-Induced Visual Perceptual Alterations.Current topics in behavioral neurosciences · 2018-01-01Phenomenology, Structure, and Dynamic of Psychedelic States.Current topics in behavioral neurosciences · 2018-01-01Two dose investigation of the 5-HT-agonist psilocybin on relative and global cerebral blood flow.NeuroImage · 2017-10-01Effect of Psilocybin on Empathy and Moral Decision-Making.The international journal of neuropsychopharmacology · 2017-09-01LSD Increases Primary Process Thinking via Serotonin 2A Receptor Activation.Frontiers in pharmacology · 2017-01-01Effects of serotonin 2A/1A receptor stimulation on social exclusion processing.Proceedings of the National Academy of Sciences of the United States of America · 2016-05-03Modulatory effect of the 5-HT1A agonist buspirone and the mixed non-hallucinogenic 5-HT1A/2A agonist ergotamine on psilocybin-induced psychedelic experience.European neuropsychopharmacology: the journal of the European College of Neuropsychopharmacology · 2016-04-01The mixed serotonin receptor agonist psilocybin reduces threat-induced modulation of amygdala connectivity.NeuroImage. Clinical · 2016-01-01Psilocybin-Induced Decrease in Amygdala Reactivity Correlates with Enhanced Positive Mood in Healthy Volunteers.Biological psychiatry · 2015-10-15Spatiotemporal brain dynamics of emotional face processing modulations induced by the serotonin 1A/2A receptor agonist psilocybin.Cerebral cortex (New York, N.Y.: 1991) · 2014-12-01Activation of serotonin 2A receptors underlies the psilocybin-induced effects on α oscillations, N170 visual-evoked potentials, and visual hallucinations.The Journal of neuroscience: the official journal of the Society for Neuroscience · 2013-06-19Psilocybin biases facial recognition, goal-directed behavior, and mood state toward positive relative to negative emotions through different serotonergic subreceptors.Biological psychiatry · 2012-12-01Mismatch negativity encoding of prediction errors predicts S-ketamine-induced cognitive impairments.Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology · 2012-03-01Psilocybin-induced deficits in automatic and controlled inhibition are attenuated by ketanserin in healthy human volunteers.Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology · 2012-02-01Prediction of psilocybin response in healthy volunteers.PloS one · 2012-01-01Acute, subacute and long-term subjective effects of psilocybin in healthy humans: a pooled analysis of experimental studies.Journal of psychopharmacology (Oxford, England) · 2011-11-01The 5-HT2A/1A agonist psilocybin disrupts modal object completion associated with visual hallucinations.Biological psychiatry · 2011-03-01The neurobiology of psychedelic drugs: implications for the treatment of mood disorders.Nature reviews. Neuroscience · 2010-09-01Psychometric evaluation of the altered states of consciousness rating scale (OAV).PloS one · 2010-08-31GMP-compliant radiosynthesis of [18F]altanserin and human plasma metabolite studies.Applied radiation and isotopes: including data, instrumentation and methods for use in agriculture, industry and medicine · 2009-04-01Serotonin research: contributions to understanding psychoses.Trends in pharmacological sciences · 2008-09-01Effects of varied doses of psilocybin on time interval reproduction in human subjects.Neuroscience letters · 2008-04-11Psilocybin links binocular rivalry switch rate to attention and subjective arousal levels in humans.Psychopharmacology · 2007-12-01The effects of the preferential 5-HT2A agonist psilocybin on prepulse inhibition of startle in healthy human volunteers depend on interstimulus interval.Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology · 2007-09-01Effects of psilocybin on time perception and temporal control of behaviour in humans.Queensland's institutional digital repository (The University of Queensland) · 2006-05-18Using psilocybin to investigate the relationship between attention, working memory, and the serotonin 1A and 2A receptors.Journal of cognitive neuroscience · 2005-10-01Modulating the rate and rhythmicity of perceptual rivalry alternations with the mixed 5-HT2A and 5-HT1A agonist psilocybin.Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology · 2005-06-01Psilocybin impairs high-level but not low-level motion perception.Neuroreport · 2004-08-26Acute psychological and physiological effects of psilocybin in healthy humans: a double-blind, placebo-controlled dose-effect study.Psychopharmacology · 2004-03-01[Hallucinogens, amphetamines and entactogens].Therapeutische Umschau. Revue therapeutique · 2003-06-01Effects of the 5-HT2A agonist psilocybin on mismatch negativity generation and AX-continuous performance task: implications for the neuropharmacology of cognitive deficits in schizophrenia.Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology · 2003-01-01Mismatch negativity predicts psychotic experiences induced by NMDA receptor antagonist in healthy volunteers.Biological psychiatry · 2002-03-01Brain mechanisms of hallucinogens and entactogens.Dialogues in clinical neuroscience · 2001-12-01A systems model of altered consciousness: integrating natural and drug-induced psychoses.Brain research bulletin · 2001-11-155-HT modulation of dopamine release in basal ganglia in psilocybin-induced psychosis in man--a PET study with [11C]raclopride.Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology · 1999-05-01Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action.Neuroreport · 1998-12-01Advances and pathophysiological models of hallucinogenic drug actions in humans: a preamble to schizophrenia research.Pharmacopsychiatry · 1998-07-01Positron emission tomography and fluorodeoxyglucose studies of metabolic hyperfrontality and psychopathology in the psilocybin model of psychosis.Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology · 1997-05-01